The Paradigm Biopharmaceuticals share price is up 196% in 2019

The Paradigm Biopharmaceuticals Ltd (ASX:PAR) share price is pushing higher again on Thursday. Is this a small cap healthcare share to buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was on form again on Thursday.

The biopharmaceutical company's shares pushed 4% higher to $2.93 on the day of its annual general meeting.

This latest gain means the Paradigm share price is now up 196% from 99 cents at the start of the year.

Why did the Paradigm share price push higher today?

This morning Paradigm released its annual general meeting presentation which reminded investors of the massive market opportunity its ZILOSUL drug has.

ZILOSUL is the brand name of its repurposing of Pentosan Polysulfate Sodium (PPS). This is an FDA-approved drug that has been used safely for treating inflammation for over sixty years.

Paradigm is focusing on repurposing PPS to treat osteoarthritis (OA). This is a market with over 31 million sufferers in the United States alone.

Things look very promising for ZILOSUL. Its Phase 2b trial in OA successfully met primary, secondary, and exploratory endpoints.

The company is now planning to file an Investigational New Drug Application (IND) with the FDA for a phase 3 clinical trial in early 2020. Which means there is the potential for a trial readout and regulatory submission in the United States as early as 2021.

Will it be worth the wait?

As you can see on the chart below, the company estimates that ZILOSUL has the potential to generate significant revenues.

Paradigm share price

Should you invest?

At the last count, Paradigm had 193,156,511 shares on issue. This means that it has a market capitalisation of approximately $570 million today.

Clearly if it can win even a 10% share of the U.S. market, its shares would be worth many multiples more than they are today.

This could make it worth considering if you're a patient and long-term focused investor. Especially given its cash balance of ~$75 million. These funds should comfortably see Paradigm through to a commercial launch, if it gets that far.

However, I would suggest you limit an investment to just a small part of your portfolio. After all, there's still a lot of work to do before that is even a possibility.

In addition to Paradigm, I think Clinuvel Pharmaceuticals Limited (ASX: CUV) and Medical Developments International Ltd (ASX: MVP) are worth watching closely as well.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »